Pharma BD Deal Intelligence
A $22-27M stock deal for an FDA-cleared cardiac biomarker test that never became commercially meaningful and was clinically discredited over the following decade
Full analysis, sources & comparables →Inverness will provide about $22.4 million of its common stock; IMI (AMEX:IMA) closed at $23.05 the day of announcement, down 81 cents.
Ischemia Technologies Incorporated (Denver, Colorado) used these findings to develop the Albumin Cobalt Binding test (ACB) that was approved in 2003 by the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
~$22.4M Inverness common stock; acute coronary syndrome biomarker (albumin cobalt binding test)
A $22-27M stock deal for an FDA-cleared cardiac biomarker test that never became commercially meaningful and was clinically discredited over the following decade
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Inverness Medical Innovations Inc. / Ischemia Technologies Inc. (this deal) | 2004 | $22M | 33 |
| Inverness Medical Innovations Inc. / Abbott Laboratories Rapid Diagnostics (pregnancy / drug-of-abuse lines) | 2003 | $92M | 71 |
| Inverness Medical Innovations Inc. / Innogenetics Diagnostica y Terapeutica S.A. (IDT) | 2005 | $19M | 45 |
| Inverness Medical Innovations Inc. / Thermo BioStar, Inc. | 2005 | $52M | 31 |
| Inverness Medical Innovations Inc. / Binax Inc. | 2004 | — | — |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2004 | $7.6B | 84 |